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Abstract
Background: To improve the efficacy of first-line therapy for advanced non-small cell lung cancer (NSCLC),
additional maintenance chemotherapy may be given after initial induction chemotherapy in patients who did not
progress during the initial treatment, rather than waiting for disease progression to administer second-line
treatment. Maintenance therapy may consist of an agent that either was or was not present in the induction
regimen. The antifolate pemetrexed is efficacious in combination with cisplatin for first-line treatment of advanced
NSCLC and has shown efficacy as a maintenance agent in studies in which it was not included in the induction
regimen. We designed a phase III study to determine if pemetrexed maintenance therapy improves progression-
free survival (PFS) and overall survival (OS) after cisplatin/pemetrexed induction therapy in patients with advanced
nonsquamous NSCLC. Furthermore, since evidence suggests expression levels of thymidylate synthase, the primary
target of pemetrexed, may be associated with responsiveness to pemetrexed, translational research will address
whether thymidylate synthase expression correlates with efficacy outcomes of pemetrexed.
Methods/Design: Approximately 900 patients will receive four cycles of induction chemotherapy consisting of
pemetrexed (500 mg/m
2) and cisplatin (75 mg/m
2) on day 1 of a 21-day cycle. Patients with an Eastern
Cooperative Oncology Group performance status of 0 or 1 who have not progressed during induction therapy will
randomly receive (in a 2:1 ratio) one of two double-blind maintenance regimens: pemetrexed (500 mg/m
2 on day
1 of a 21-day cycle) plus best supportive care (BSC) or placebo plus BSC. The primary objective is to compare PFS
between treatment arms. Secondary objectives include a fully powered analysis of OS, objective tumor response
rate, patient-reported outcomes, resource utilization, and toxicity. Tumor specimens for translational research will
be obtained from consenting patients before induction treatment, with a second biopsy performed in eligible
patients following the induction phase.
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Background
More than 75% of patients with non-small cell lung can-
cer (NSCLC) present with locally advanced (stage IIIB)
or metastatic (stage IV) disease [1]. Treatment for these
patients includes chemotherapy, radiotherapy, and best
supportive care (BSC), with current guidelines recom-
mending platinum-based combination regimens as first-
line treatment [2,3]. Although improvement has been
achieved over the last few decades, the prognosis for
these patients remains poor, with response rates for
first-line therapy of 20% to 40% and median survival
times of 7 to 12 months [3,4].
Numerous efforts have been made to improve the effi-
cacy of first-line therapy for advanced NSCLC. Although
differing in tolerability, standard platinum-based doub-
lets have not appeared to differ in efficacy. For example,
in a randomized phase III study comparing cisplatin/
gemcitabine, cisplatin/paclitaxel, cisplatin/docetaxel, and
carboplatin/paclitaxel, all of the regimens demonstrated
comparable median overall survival (OS) [5]. Likewise,
in another study comparing the first two of the previous
doublets to cisplatin/vinorelbine, a superior regimen was
not identified [6]. Various non-platinum-containing regi-
mens have also been tested, but none have been proven
superior [3]. Additionally, prolonged first-line treatment
does not appear beneficial [7-10].
Molecular targeted therapy has recently been examined
as a means to improve the efficacy of advanced NSCLC
first-line therapy. The epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors erlotinib and gefitinib
did not improve efficacy when added to a platinum doub-
let [11]. They were active, however, as single agents in
the second- and third-line setting, particularly in patients
with EGFR mutations [11,12]. Cetuximab and bevacizu-
mab, monoclonal antibodies against the EGFR and the
vascular endothelial growth factor, respectively, resulted
in improved survival when added to standard first-line
therapy [13-16]. However, cetuximab is not currently
approved for NSCLC treatment, and toxicity limits the
use of bevacizumab to nonsquamous tumors [17]; there-
fore, platinum-based chemotherapy doublets remain the
treatment of choice for many patients.
Another means of optimizing first-line therapy has
been to examine whether superior treatment outcome is
associated with specific patient or disease characteristics.
In a phase III study in patients with advanced NSCLC, a
preplanned subgroup analysis showed a difference in
response by tumor histology [18,19]. Patients with non-
squamous histology (n = 1000) had statistically superior
OS with cisplatin/pemetrexed than cisplatin/gemcitabine
(11.0 versus 10.1 months; hazard ratio [HR] = 0.844,
p = 0.011) [19]. A retrospective analysis of previous
pemetrexed phase III trials confirmed the favorable effi-
cacy seen with pemetrexed in nonsquamous NSCLC
[19]. The differential responsiveness seen may be asso-
ciated with differences in thymidylate synthase (TS), the
primary target of the antifolate pemetrexed [20,21]. TS
levels are approximately 1.5-fold lower in adenocarci-
noma compared with squamous cell carcinoma [22,23].
Preclinical evidence suggests that high levels of TS may
indicate lowered sensitivity to antifolates [24,25].
In addition to the identification of novel agents and
combinations for first-line treatment of advanced
NSCLC, efforts have focused on improving efficacy and
tolerability via alterations in the treatment schedule
[26-28]. In maintenance therapy (also referred to as con-
solidation therapy), the duration of chemotherapy is
prolonged by administering additional drugs in patients
who have not progressed or who have achieved a
response during the initial or induction chemotherapy.
It is administered for either a defined number of cycles
or until progressive disease. The goals of maintenance
therapy are to improve OS, slow disease progression,
and maintain or improve the quality of life without
untoward side effects.
Post-induction maintenance therapy has the theoretical
advantage of allowing patients to continue chemotherapy
while the tumor burden is low (compared to treatment
after disease progression). By using a different drug for
maintenance therapy than that used in the induction
regimen, patients are exposed to a chemotherapeutic
agent with a different mechanism of action. Alternatively,
using the same drug for maintenance therapy that was
effective during the induction regimen offers the practical
advantage of continuing a beneficial chemotherapy with
the favorable toxicity profile of a single-agent treatment.
In fact, Grossi and colleagues [27] have likened the
induction phase to an in-vivo drug-sensitivity assay
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response to the induction therapy (either response or
stable disease), and who are thus more likely to benefit
from maintenance chemotherapy with one of the drugs
included in the induction regimen.
One of the first phase III studies that explored main-
tenance therapy examined gemcitabine maintenance
therapy following four cycles of induction therapy with
cisplatin/gemcitabine [29]. Patients without progressive
disease following induction therapy randomly received
either gemcitabine or BSC. The median time to progres-
sive disease was significantly longer in patients who
received gemcitabine maintenance therapy versus BSC.
Additionally, a significantly longer OS time occurred in
patients with a high baseline Karnofsky performance sta-
tus (PS) (>80) who were treated with gemcitabine com-
pared with BSC, whereas the difference in survival was
not statistically significant between arms in patients with
a low baseline performance status. A recent phase III
study compared docetaxel given either immediately after
4 cycles of carboplatin/gemcitabine (as a maintenance
therapy) or after disease progression (as a second-line
therapy) [30]. A statistically significant improvement in
progression-free survival (PFS) and a numerical increase
in OS were observed in patients who received docetaxel
as maintenance therapy.
Because of the efficacy of pemetrexed in second-line
NSCLC [31], its favorable safety profile, and its ease of
administration (a 10-minute infusion), a phase III study
examined pemetrexed (versus placebo) as maintenance
therapy in patients who had not progressed following
administration of one of six non-pemetrexed-containing,
commonly prescribed induction regimens: carboplatin/
gemcitabine, cisplatin/gemcitabine, carboplatin/doce-
taxel, cisplatin/docetaxel, carboplatin/paclitaxel, or cis-
platin/paclitaxel [32,33]. Pemetrexed maintenance
therapy resulted in a statistically significant and clini-
cally relevant increase in OS and PFS in the overall and
nonsquamous populations [33]. The improved efficacy
observed in patients with nonsquamous tumors con-
firmed previous findings for pemetrexed in NSCLC
[18,19]. The study also demonstrated that pemetrexed
maintenance therapy was well tolerated [34].
Given the efficacy of pemetrexed in combination with
cisplatin as a first-line doublet and as a maintenance
agent (when not used in the induction regimen), we
designed a phase III study to determine if pemetrexed
maintenance therapy will improve efficacy over placebo
following cisplatin/pemetrexed induction therapy in
patients with advanced nonsquamous NSCLC. Further-
more, translational research will address whether TS
expression correlates with efficacy outcomes in patients
treated with pemetrexed.
Methods
Objectives
The primary objective of this study is to compare PFS of
pemetrexed maintenance therapy plus BSC versus pla-
cebo plus BSC in patients with stage IIIB or IV non-
squamous NSCLC whose disease has not progressed
during four cycles of pemetrexed and cisplatin induction
chemotherapy.
Secondary objectives of the study are to compare the
following between treatment arms: OS; objective tumor
response rate (assessed using Response Evaluation Cri-
teria in Solid Tumors [RECIST] [35]); patient-reported
outcomes (using the EuroQol 5-dimensional scale [EQ-
5D] [36]); resource utilization; and toxicity (adverse
events graded using Common Terminology Criteria for
Adverse Events [CTCAE] [Version 3.0] [37]). The objec-
tive of the translational research component of the
study is to examine the association between TS expres-
sion and efficacy outcomes.
Study Design and Treatment Plan
The study will have two treatment phases: an unblinded
induction phase and a blinded maintenance phase
(Figure 1). In the induction phase, eligible patients will
receive four cycles of induction chemotherapy consisting
of pemetrexed (500 mg/m
2)a n dc i s p l a t i n( 7 5m g / m
2)
on day 1 of a 21-day cycle.
Following completion of cycle 4 of induction treat-
ment, eligible patients will be randomly assigned to one
of two double-blind maintenance regimens: pemetrexed
500 mg/m
2, administered intravenously on day 1 every
21 days, plus BSC (pemetrexed arm); or approximately
100 mL normal saline (0.9% sodium chloride), adminis-
tered intravenously on day 1 every 21 days, plus BSC
(placebo arm). Maintenance chemotherapy will begin at
t h et i m eo fr a n d o m i z a t i o no ram a x i m u mo f7d a y s
from the date of randomization. Patients must start
maintenance therapy no earlier than 21 days and no
later than 42 days from day 1 of the fourth cycle of
induction therapy. Randomization to treatment arm will
be stratified by the following prognostic factors: Eastern
Cooperative Oncology Group (ECOG) PS just prior to
randomization (0 versus 1), tumor response to induction
chemotherapy (complete/partial response [CR/PR] ver-
sus stable disease [SD]), and disease stage prior to
administration of induction therapy (IIIB versus IV).
Maintenance therapy will end when the patient meets
one of the prespecified reasons for discontinuation,
including disease progression. Patients who discontinue
maintenance treatment without progressive disease will
continue to receive periodic tumor response evaluation.
Once a patient has progressed, follow up will occur
every 90 days until death or study closure. Information
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surgical intervention will be collected during the post-
discontinuation period.
During the study, all patients will receive standard folic
acid and vitamin B12 supplementation and prophylactic
dexamethasone, as specified in the pemetrexed label.
The protocol will be approved by each participating
institutional ethics review board. The study will be con-
ducted in accordance with the ethical principles of the
Declaration of Helsinki and good clinical practice. All
patients will sign written informed consent before
treatment.
Study Population
Patients will be eligible for participation in the induction
phase of the study if they have: histologic or cytologic
diagnosis of advanced (stage IIIB with pleural effusion
and/or positive supraclavicular lymph nodes or stage IV)
nonsquamous NSCLC; no prior systemic chemotherapy
for lung cancer; ≥1 measurable lesion; an ECOG PS of 0
or 1; adequate organ function; and ≥18 years of age.
Patients will be ineligible for the study if they have pre-
dominantly squamous cell and/or mixed small cell, non-
small cell histology, or are receiving concurrent adminis-
tration of any other antitumor therapy. Patients will be
eligible for randomization and treatment in the
maintenance phase of the study if they: complete four
cycles of induction therapy; have documented (con-
firmed or unconfirmed) radiographic evidence of CR,
PR, or SD after completion of induction chemotherapy;
and have an ECOG PS of 0 or 1. Table 1 lists the elig-
ibility criteria for both phases of the study.
Statistical Analysis Plan
A minimum of 558 qualified patients will be randomly
assigned in a 2:1 ratio to maintenance therapy of peme-
trexed plus BSC (372 patients) or placebo plus BSC (186
patients) to provide at least 238 PFS events (52% censor-
ing) for the primary efficacy analysis. Assuming a true
PFS HR of 0.65, the primary unadjusted log-rank test of
PFS will have 90% power to show a statistical difference
between arms. In order to randomize at least 558 quali-
fied patients, approximately 900 patients will be treated
during the induction phase.
OS will be analyzed at the time of the primary PFS
analysis and at the end of the study. Assuming the true
OS HR is 0.70, the final unadjusted log-rank test of OS
will have 93% power to show a statistical difference
between arms provided there are 390 events (30% cen-
soring). To maintain an overall two-sided alpha level of
5% for the analyses of PFS and OS, a statistical gate-
keeping and alpha-spending strategy will be applied.
Figure 1 Study Design. Abbreviations: BSC = best supportive care. aPemetrexed (500 mg/m2, day 1) plus cisplatin (75 mg/m2, day 1).
bPemetrexed (500 mg/m2, day 1). cAfter completion of 4 cycles of induction treatment, eligible patients without disease progression will be
randomized 2:1 to receive pemetrexed plus BSC or placebo plus BSC during the double-blind maintenance phase of the study.
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done for the induction and maintenance phases of the
study. For the induction phase, the population will consist
of patients receiving at least one dose of either pemetrexed
or cisplatin. For the maintenance phase, all patients who
were randomized to a treatment arm will be eligible for
baseline, efficacy, and safety analyses. The primary analysis
of PFS will compare maintenance pemetrexed to placebo,
calculated from the time of randomization following com-
pletion of induction treatment to the first date of objec-
tively determined PD or death from any cause.
The Kaplan-Meier method [38] will be used for OS and
PFS time-to-event analyses; the Cox proportional hazards
model [39] will be used to estimate HRs with assigned
treatment as the only covariate. Tumor response rates
(PR + CR) and disease control rates (CR + PR + SD) will
be compared between randomization arms using the
Fisher’s exact test. The tumor response to maintenance
therapy will use the last radiologic assessment before ran-
domization as baseline. The tumor response to whole
treatment (induction and maintenance) will use the radi-
ologic assessment before induction therapy as baseline.
For patient-reported outcomes analyses, all enrolled
patients with a baseline and ≥1 EQ-5D survey will be
included in the assessment. EQ-5D findings will be
summarized for all patients enrolled at baseline, at each
cycle of the induction phase, and at each cycle during
the maintenance phase by treatment arm. Mean index
and visual analog scale scores will be calculated and
analyzed using a mixed effect analysis of variance
model. Analysis of resource utilization will include all
patients treated with study therapy.
Translational Research
Patients are eligible to participate in this component of
the study if they have achieved a CR, PR, or SD during
the induction phase of the study, have tissue obtained
from a biopsy prior to starting induction treatment, and
have provided informed consent for the collection of a
second biopsy before beginning maintenance treatment.
Both tissue biopsies must be formalin-fixed and paraffin
embedded, with tissue blocks preferred over slides.
Intratumoral mRNA expression will be measured in a
central laboratory using quantitative polymerase chain
reaction techniques. A minimum of 100 paired speci-
mens (baseline and second biopsy samples) will be col-
lected to examine if TS expression correlates with
efficacy outcomes of pemetrexed. Other lung and peme-
trexed biomarkers will be evaluated if sufficient tissue is
available.
Table 1 Key Patient Selection Criteria
Induction Phase
Inclusion Criteria Exclusion Criteria
￿ Histologic or cytologic diagnosis of advanced, nonsquamous NSCLC
￿ Stage IIIB (with pleural effusion and/or positive supraclavicular lymph
nodes) or IV disease prior to induction therapy not amenable to curative
therapy
￿ Prior radiation therapy to <25% of the bone marrow (not including
whole pelvis radiation) if completed and patient has recovered 30 days
before enrollment
￿ ≥1 unidimensionally measurable lesion as defined by RECIST
￿ Males and females ≥18 years of age
￿ Performance status of 0 or 1 on the ECOG scale
￿ Estimated life expectancy of ≥12 weeks
￿ Adequate organ function (bone marrow reserve, renal, hepatic)
￿ Use of an approved contraceptive method by male and female patients
with reproductive potential
￿ Negative serum or urine pregnancy test within 7 days before study
enrollment for women with childbearing potential
￿ Ability to comply with study and/or follow-up procedures
￿ Signed informed consent document
￿ Squamous cell and/or mixed small cell, non-small cell histology
￿ Prior systemic chemotherapy for lung cancer, including adjuvant
therapy, for any stage of NSCLC
￿ Concurrent administration of any other antitumor therapy
￿ Treatment within last 30 days with a drug that has not received
regulatory approval
￿ Prior participation in a study investigating pemetrexed
￿ Serious concomitant systemic disorder that would compromise ability
to adhere to the protocol
￿ Serious cardiac condition, such as myocardial infarction, angina, or
heart disease
￿ Prior malignancy other than NSCLC, carcinoma in situ of the cervix, or
nonmelanoma skin cancer unless malignancy diagnosed and treated ≥5
years previously without recurrence
￿ Central nervous system metastases unless the patient has completed
successful local therapy and has been off corticosteroids for ≥4 weeks
￿ Clinically significant third space fluid collection that cannot be
controlled by drainage or other procedure
￿ Inability to interrupt aspirin or other nonsteroidal anti-inflammatory
drugs, other than an aspirin dose ≤1.3 g per day, for a 5-day period
￿ Inability or unwillingness to take folic acid, vitamin B12
supplementation, or corticosteroids
Maintenance Phase
Inclusion criteria
￿ ECOG PS of 0 or 1
￿ Documented radiographic evidence of a complete or partial tumor
response or stable disease*
￿ Completion of four cycles of induction chemotherapy
RECIST = Response Evaluation Criteria in Solid Tumors; ECOG PS = Eastern Cooperative Oncology Group performance status.
*Tumor assessment must occur between cycle 4 (day 1) of induction therapy and the date of randomization. This response does not have to be confirmed in
order for the patient to be randomized.
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This trial examines whether pemetrexed maintenance
therapy following four cycles of cisplatin/pemetrexed
induction therapy provides an efficacy benefit without
substantially affecting patient safety. As noted by Grossi
and colleagues [27], a study design such as ours enables
us to select only those patients responsive to peme-
trexed to continue with pemetrexed maintenance treat-
ment. To better understand the molecular mechanism
of pemetrexed responsiveness, TS gene expression
before and after induction therapy will be measured and
correlated with the efficacy results.
Two phase III studies in patients with NSCLC have
examined a platinum-based induction doublet followed
immediately by maintenance therapy composed of the
non-platinum agent of the induction regimen. In one
study by Brodowicz and colleagues, gemcitabine mainte-
nance therapy was administered following cisplatin/gem-
citabine induction therapy [29]. In a second study,
paclitaxel maintenance therapy was administered follow-
ing carboplatin/paclitaxel induction therapy [40,41]. In
both studies, patients who continued to receive the non-
platinum agent of the induction regimen as maintenance
therapy had better outcomes than patients who received
no maintenance therapy.
The efficacy and safety of pemetrexed as a maintenance
therapy has been examined in a small study of patients
with malignant pleural mesothelioma [42]. Patients
received six cycles of pemetrexed-containing induction
therapy composed of either carboplatin/pemetrexed or
pemetrexed monotherapy (for patients who had prior
first-line therapy). Patients receiving pemetrexed mainte-
nance therapy showed promising increases in time to
progression and OS. Additionally, pemetrexed mainte-
nance therapy was well tolerated, with no grade 4 toxicity
observed, and fatigue and neutropenia as the only grade
3 events occurring in more than one patient (2 each).
The safety of maintenance pemetrexed following
induction treatment with pemetrexed/cisplatin will also
be assessed in this study. The safety profile of peme-
trexed/cisplatin is well established based on results from
two phase III studies in advanced NSCLC [18] and
malignant pleural mesothelioma [43]. The safety of sin-
gle-agent pemetrexed administered as maintenance
[32,33] and second-line treatment of advanced NSCLC
[31] has also been established. In the maintenance
study, the safety of long-term pemetrexed exposure was
evaluated in patients who received 10 or more cycles of
maintenance pemetrexed (N = 98) following induction
therapy with a non-pemetrexed-containing regimen.
There was no significant difference in drug-related
g r a d e3 / 4a d v e r s ee v e n t sf o rt h e s ep a t i e n t sc o m p a r e d
with those who received less than 10 cycles [33].
In an effort to improve the effectiveness of first-line
cisplatin/pemetrexed therapy for advanced nonsqua-
mous NSCLC, this study examines pemetrexed main-
tenance therapy immediately following four cycles of
induction therapy. Evidence suggests that following a
platinum-containing induction doublet with mainte-
nance therapy using the non-platinum agent of the
induction regimen enables the identification of
patients most likely to benefit from the maintenance
treatment.
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